Researchers at the University of Louisville, Kentucky, have demonstrated that a new radiotracer, 2-18F-fluorodeoxysorbitol (18F-FDS), can identify and track bacterial infection in lungs better than current imaging methods and is able to differentiate bacterial infection from inflammation.
“Currently, bacterial infections can be diagnosed only after they have become systemic or have caused significant anatomical tissue damage, a stage at which they are challenging to treat owing to the high bacterial burden,” explains Chin K. Ng, PhD, at the University of Louisville School of Medicine, Louisville, Kentucky.
He points out, “18F-FDG PET, a widely commercially available imaging agent, is capable of imaging infection, but it cannot distinguish infections from other pathologies such as cancer and inflammation. Therefore, there is a great need to develop imaging agents with high specificity and sensitivity. There are still no specific imaging agents that can differentiate bacterial infection from sterile inflammation at an early stage.”
For this study, mice were inoculated with either live Klebsiella pneumoniae bacteria to induce lung infection, or the dead form of the bacteria to induce inflammation. Half of the mice with the live bacteria were imaged with PET/CT using either 18F-FDS or 18F-FDG on days 0, 1, 2 and 3 to monitor disease progression post infection. The other half were screened by bioluminescent imaging, and mice with visible infection were selected for follow-up PET/CT scans with 18F-FDS. For the inflammation group, half the mice were imaged with PET/CT using 18F-FDS and half using 18F-FDG from day 1 to day 4 post-inoculation.
While both 18F-FDS and 18F-FDG effectively tracked the degree of bacterial infection measured by bioluminescent optical imaging, only 18F-FDS was able to differentiate lung infection from lung inflammation.
Ng notes, “Bacterial infection represents a threat to human health, including hospital-acquired, implant-related, and multidrug-resistant infections. 18F-FDS whole-body PET/CT imaging in mice has shown to be a unique imaging technique that could differentiate infection from inflammation. This same technique could potentially be used in patients to identify infection sites and determine the bacterial infection class, so that patients could avoid taking antibiotics that are known to have no effect against specific bacteria.”
He adds, “The interpretation of CT appearances of lung disorders can be complex if a differential diagnosis needs to distinguish between inflammation and infection. Thus 18F-FDS PET/CT could be initially used as a follow up after an inconclusive CT diagnosis for suspected bacterial lung infection. As proven clinical data accumulate over time, 18F-FDS PET/CT could become a new clinical standard for confirming bacterial infection in the lungs or other sites.”
Looking ahead to making 18F-FDS clinically available, Ng states, “Since 18F-FDS can be made from 18F-FDG with one extra, simple conversion step, and sorbitol has already been approved for use in humans by the U.S. Food and Drug Administration, the approval pathway for 18F-FDS should be straightforward. 18F-FDS would be inexpensive and readily available once approved.”
He also observes, “This and other new PET imaging agents demonstrate that molecular imaging and nuclear medicine can offer unique technologies for patient care and will continue to play a key influential role in healthcare.”

Society of Nuclear Medicine and Molecular Imaginghttps://tinyurl.com/y9n45qso

Due to overwhelming demand, the abstract submission for paper presentations and posters for the 43rd World Hospital Congress of the International Hospital Federation has been extended to 1 March.

The World Hospital Congress is a unique global forum that brings together leaders of national and international hospital and healthcare organizations to share knowledge, expertise, experiences and best practices in leadership in hospital and healthcare management and delivery of services.

The 2019 World Hospital Congress is being hosted by the Ministry of Health of the Sultanate of Oman with the over-arching theme “People at the heart of health services in peace and crisis”.

Hospitals and health service providers that want to share their programs, projects, researches and experiences with health leaders and professionals from across the globe can still submit their abstracts for the following sub-themes:

Resilient health services:

• Best practices for preparedness and responses to disasters, outbreaks and cyberattacks
• Mitigating consequences of conflicts and terror attacks to continue serving all especially vulnerable groups
• Operating under severe resource constraints
• Leading practices reflecting systematic approaches to learning from crises and trauma
• Violence in the workplace

Health investment for prosperity

• Exploring governance practices driving better efficiency and relevance
• What management and leadership can do for increased efficiency and outcomes
• Inter-professional leadership for cost effectiveness and quality improvement
• What are the impacts of hospitals in the local and national economy
• Future of hospitals in an economically constrained world

Innovation for health impact

• Removing barriers to innovation with change management
• Hospital Technology Assessment to speed up innovation adoption
• Embedding collaboration with industries for health innovation
• Procurement to accelerate and develop innovation
• Enhancing digital health services in the virtual space

More information including the submission process, general criteria and terms and conditions for presenters are available at https://congress.ihf-fih.org/ihf_abstracts

Successful abstracts will also be considered for publication in the IHF Journal and presentation in the IHF Webinars. Poster abstracts will also be entered in the Best Poster Award.

For any questions please contact congress@ihf-fih.org or visit www.worldhospitalcongress.org.

For decades, clinicians treating multiple sclerosis (MS) have interpreted the appearance of new or expanding brain lesions on magnetic resonance imaging (MRI) scans as a sign that a patient’s disease is getting worse. Now, University at Buffalo researchers are finding that it may be the atrophy or disappearance of these lesions into cerebrospinal fluid (CSF) that is a better indicator of who will develop disability.
The five-year study, conducted by MS researchers in the Jacobs School of Medicine and Biomedical Sciences at UB, was published in the Journal of Neuroimaging. Similar findings also resulted from their 10-year study of 176 patients that they presented at the annual meeting of the American Academy of Neurology (AAN) in Los Angeles in April.
Robert Zivadinov, MD, PhD, first author on the 10-year study and senior author on the five-year study, said: “Using the appearance of new brain lesions and the enlargement of existing ones as the indicator of disease progression, there was no sign of who would develop disability during five or 10 years of follow-up, but when we used the amount of brain lesion volume that had atrophied, we could predict within the first six months who would develop disability progression over long-term follow-up.”
Zivadinov, a professor of neurology in the Jacobs School and director of the Buffalo Neuroimaging Analysis Center (BNAC) in the Jacobs School, also directs the Center for Biomedical Imaging at UB’s Clinical and Translational Science Institute.
Brain lesions in general are a sign of damage to the brain, such as physical trauma, a stroke, normal aging or chronic disease. Patients with MS receive MRI scans as part of their routine care so that doctors can track the appearance of new lesions and the enlargement of existing ones, typically seen as indicators of disease progression. Approval by the Food and Drug Administration for new MS drugs typically depends on the drug’s ability to reduce the number of brain lesions over 24 months.
Zivadinov noted that according to this premise, the loss of brain lesions could inadvertently be seen as a sign that the patient’s condition is improving. MS is characterized by the loss of myelin sheaths surrounding axons in the brain and disrupting the brain’s ability to send and receive neuronal messages. The growth of new myelin sheaths around axons may demonstrate that some brain tissue has been repaired spontaneously or as the result of medication.
In order to focus specifically on the disappearance of lesions that likely indicate pathological change like atrophy, not beneficial change, like resolution or remyelination, the researchers looked exclusively at lesions seen on previous scans that were later replaced by cerebrospinal fluid.
“How do we know the lesions have disappeared?” asked Zivadinov. “Because where there was brain lesion tissue before, there now is just fluid.”
“The big news here is that we did the opposite of what has been done in the last 40 years,” said Michael G. Dwyer, PhD, assistant professor of neurology and bioinformatics in the Jacobs School and first author on the five-year study in the Journal of Neuroimaging. “Instead of looking at new brain lesions, we looked at the phenomenon of brain lesions disappearing into the cerebrospinal fluid.”
The researchers looked specifically at the rate of brain lesion loss due to atrophy compared to accumulation of lesion volume seen both at baseline and follow-up. They found that the amount of lesion volume that atrophied was the only significant lesion parameter that correlated with clinical disability as measured by the Expanded Disability Status Scale (EDSS), the most widely used method of quantifying disability in MS. 
“We didn’t find a correlation between people who developed more or larger lesions and developed increased disability,” said Dwyer, “but we did find that atrophy of lesion volume predicted the development of more physical disability.”
While patients with relapsing remitting MS showed the highest amount of new lesions during the study, patients with progressive MS — the most severe subtype — had the most accelerated volume of brain lesion atrophy. The UB researchers said this indicates that this new imaging biomarker could be particularly important in transitional phases between relapsing and progressive MS subtypes.
“Paradoxically, we see that lesion volume goes up in the initial phases of the disease and then plateaus in the later stages,” said Zivadinov. “When the lesions decrease over time, it’s not because the patient lesions are healing but because many of these lesions are disappearing, turning into cerebrospinal fluid.”
Another important scientific finding of the studies, Zivadinov continued, is that atrophied brain lesions were a more robust predictor of disability progression than the development of whole brain atrophy itself, the most accepted biomarker of neurodegeneration in MS.
“Our data suggest that atrophied lesions are not a small, secondary phenomenon in MS, and instead indicate that they may play an increasingly important role in predicting who will develop a more severe and progressive disease,” he said.

University at Buffalo
www.buffalo.edu/news/releases/2018/05/025.html

The global hip replacement implants market was valued at approximately US$ 7.0 Bn in 2017 and is anticipated to expand at a CAGR of over 3.5% from 2018 to 2026 to reach a value of approximately US$ 9.0 Bn by 2026. The global hip replacement implants market is driven by a rise in demand for hip replacement procedures, increase in government expenditure for the advancement of health care, rise in the incidence of trauma/accidental injuries, and increase in the prevalence of hip-related disorders. Furthermore, the global demand for hip replacement is increasing primarily due to a rise in clinical education among patients, increase in demand for hip replacement implants from the geriatric population, and rise in the prevalence of obesity and arthritis. Demand for new hip surgeries has significantly increased in the U.S. from 89,919 surgeries in 2004 to 122,154 in 2015.
The global hip replacement implants market has been segmented based on product, material, end-user, and region. In terms of product, the global market has been classified into total hip replacement implants, partial hip replacement implants, revision hip replacement, and hip resurfacing implants. The total hip replacement segment has been further sub-segmented into fixed bearing and mobile bearing. Based on material, the hip replacement implants market has been categorized into metal-on-metal, metal-on-polyethylene, ceramic-on-polyethylene, ceramic-on-metal, and ceramic-on-ceramic. In terms of end-user, the market has been split into hospitals, ambulatory surgical centers, orthopedic clinics, and others. Based on region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Based on product, the total hip replacements implants segment is anticipated to dominate the global hip replacement implants market, owing to a rise in the geriatric population and increase in the incidence of osteoarthritis. In terms of material, the metal-on-polyethylene segment dominated the global hip replacements implants market in 2017. Based on end-user, the hospitals segment accounted for a prominent share of the market in 2017. It is expected to dominate the market during the forecast period. Increase in patient population and improvement in health care infrastructure are expected to drive the segment during the forecast period.
North America constituted a prominent share of the global market in 2017. Rise in the prevalence of orthopedic injuries, increase in health care expenditure, rise in mergers & acquisitions, and robust product pipeline are anticipated to drive the market in the region during the forecast period. The dominance of the region is attributed to a rise in the incidence of osteoarthritis and osteonecrosis diseases. Additionally, an aging population, rapid innovation in technology, and high R&D expenditure are fuelling the hip replacement implants market in North America and Europe. Rise in demand for hip replacement implants in emerging economies, such as China and India, expansion of the health care industry, and a rapid rise in the patient population are anticipated to fuel the market in Asia Pacific in the next few years. The hip replacement implants market in Latin America and Middle East & Africa is expected to be driven by a rise in government initiatives to promote better health care facilities and increase in investment in the health care sector during the forecast period. Increase in disposable income, rapid urbanization, increase in health care infrastructure, and distribution and partnership strategies adopted by key players are driving the market in emerging regions.

To know more about this research report, please visit our Report: https://www.transparencymarketresearch.com/hip-replacement-implants-market.html

Wearable biosensors have grown increasingly popular as many people use them in wristbands or watches to count steps or track sleep. But there is not enough proof that these devices are improving patient outcomes such as weight or blood pressure, according to a study by Cedars-Sinai investigators.
“As of now, we don’t have enough evidence that they consistently change clinical outcomes in a meaningful way,” said senior author Brennan Spiegel, MD, director of Cedars-Sinai Health Services Research. “But that doesn’t mean they can’t.”
Wearable biosensors—non-invasive devices that automatically transmit data to a web portal or mobile app for patient self-monitoring or health provider assessment—have been touted as a means to reduce healthcare utilization, decrease costs, generate research data and increase physician satisfaction.
In their literature analysis, Spiegel and his co-authors found that remote patient monitoring with these sensors had no statistically significant impact on any of six clinical outcomes studied: body mass index, weight, waist circumference, body fat percentage, systolic blood pressure and diastolic blood pressure. The analysis found that these devices did show early promise in improving outcomes for certain conditions, including obstructive pulmonary disease, Parkinson’s disease, hypertension and low back pain.
“There is a big difference between using these sensors to track sleep for self-betterment and using them to make medical decisions,” said co-author Michelle S. Keller, MPH, a clinical research specialist at the Cedars-Sinai Center for Outcomes Research and Education.
Investigators did a statistical analysis and in-depth literature review of 27 studies from 13 countries published between January 2000 and October 2016. Each study examined the effects of remote patient monitoring using wearable biosensors.
The interventions targeted patients who were overweight or had heart disease, lung disease, chronic pain, stroke or Parkinson’s. The devices studied included physical activity trackers, blood pressure monitors, electrocardiograms, electronic weight scales, accelerometers (devices measuring acceleration) and pulse oximeters (oxygen saturation monitors), among others. These devices were embedded in everything from watches and belts to skin patches and textiles.
A statistical analysis of the relevant literature revealed that remote patient monitoring resulted in no significant impact on any of the reported clinical outcomes. Certain types of interventions worked best, including efforts grounded in social science models and established care guidelines and those that used personalized coaching.
Lack of data may be the culprit. Of more than 4,000 studies the authors initially reviewed, fewer than 1 percent were eligible to be included in the study, and only 16 were considered high-quality research. The authors found very few randomized controlled trials for each of the clinical outcomes analysed, and studies varied significantly in terms of the types of devices used, the populations studied and the interventions tested.
“Many of the studies we reviewed were still in the pilot phase,” said lead author Benjamin Noah, a clinical research associate at the Center for Outcomes Research and Education. “There just is not enough data yet.

Cedars – Sinai Hospitalhttps://tinyurl.com/yaw3kupv